Study of HS-10390 for IgA nephropathy
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new medicine called HS-10390 to see if it can help people with IgA nephropathy, a kidney disease. It aims to reduce protein in the urine and protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with IgA nephropathy through a kidney biopsy.
- You have been taking a stable dose of blood pressure medicine (ACEI or ARB) for at least 12 weeks.
- Your urine protein level is at least 0.75 grams per day.
- Your kidney function (eGFR) is 30 or higher.
- Your blood pressure is within a certain range (systolic 100-150, diastolic 60-100).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called HS-10542 for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and helps reduce protein in the urine, which is a sign of kidney damage.
This study tests a new medicine called CM313 for people with IgA nephropathy, a kidney disease. The goal is to see if it can help reduce protein in the urine and protect kidney function.
This phase 3 trial tests an experimental drug (HRS-5965) for people with IgA nephropathy (a kidney disease). It aims to find out if the drug can help reduce protein in the urine and protect kidney function. To join, you must have had a kidney biopsy showing IgA nephropathy within the past 8 years and have significant protein in your urine despite taking standard treatments.
This study continues treatment with an experimental medicine called HSK39297 for people with IgA nephropathy, a condition where the immune system damages the kidneys. The trial will track how safe and effective the medicine is over time in people who already completed an earlier study.
This trial tests a new medicine (FXS6837) for people with IgA nephropathy (a kidney disease that causes protein in the urine and can lead to kidney damage). The goal is to see if it can reduce protein loss and protect kidney function.
This trial tests a new medication for IgA nephropathy, a kidney disease that causes inflammation and protein loss in urine. It aims to see if the drug can safely slow down kidney damage and protect kidney function.
Hear when a new Immunoglobulin A Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.